Rate of functional decline in Huntington's disease. Huntington Study Group.
about
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of NeurologyDeterminants of functional disability in Huntington's disease: role of cognitive and motor dysfunctionNeural stem cells could serve as a therapeutic material for age-related neurodegenerative diseasesSex Differences in Circadian Dysfunction in the BACHD Mouse Model of Huntington's DiseaseRating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.Suicidal ideation in Huntington disease: the role of comorbidityComorbidities of obsessive and compulsive symptoms in Huntington's disease.Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participantsObjective acoustic quantification of phonatory dysfunction in Huntington's diseaseRegional atrophy associated with cognitive and motor function in prodromal Huntington disease.An overview of psychiatric symptoms in Huntington's disease.Nonparametric estimation for censored mixture data with application to the Cooperative Huntington's Observational Research Trial.Basal ganglia volumetric studies in affective disorder: what did we learn in the last 15 years?Neural bases of dysphoria in early Huntington's disease.Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families.Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington diseaseQEEG Measures in Huntington's Disease: A Pilot Study.Cognitive deficits in Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological Status.Identifying the "source" of recognition memory deficits in patients with Huntington's disease or Alzheimer's disease: evidence from the CVLT-IINeuropsychiatric Burden in Huntington's Disease.A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's diseaseLongitudinal Change in Gait and Motor Function in Pre-manifest Huntington's Disease.Genetic connections between neurological disorders and cholesterol metabolismAge-at-onset in Huntington disease.Challenges assessing clinical endpoints in early Huntington disease.Gait in Huntington's disease and the stride length-cadence relationshipOnset of Huntington's disease: can it be purely cognitive?Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.Tracking motor impairments in the progression of Huntington's disease.Tapping linked to function and structure in premanifest and symptomatic Huntington diseaseAntisense therapy in neurologyMotor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.Awareness of memory deficits in early stage Huntington's disease.Everyday cognition in prodromal Huntington diseaseCoordination of fingertip forces during precision grip in premanifest Huntington's diseaseEffectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review.
P2860
Q24621818-B327A09E-4083-4640-9C8C-69E6C8D43DA6Q26866192-24E253A3-1A4C-4D58-B4B8-7348F4779DBFQ27021719-8A11E1BC-CBDB-4ED6-ACAC-9AD9D5942CEEQ28386809-05F89D1D-A2E5-4B29-B67F-8BEBC6CB3D1DQ30249645-AD8D0F9D-ED80-4605-962F-3D45B37B2EA2Q30250276-355A2D7E-36D9-4B3C-B387-307854D81A4FQ30416862-1F3DDB40-F065-4FEF-BE7D-ADD8297BD5F6Q30430896-0C6311E0-F8B5-43CA-86D3-68AB0454D10AQ30435217-98B4A107-33C1-4F8D-B79F-A956D96AD327Q30453596-84ECF82C-6E32-4E61-9A1E-5BD7080C5DF3Q30644807-ADC21AEC-4F9C-44EA-9CE8-35042D823C5BQ30660685-AF4C6A2F-ABBA-4CD9-82DA-4D8C58CFC1D6Q30747024-B5A2253A-D42C-4CBF-A0F9-AF0CEC5D999EQ31013562-FCD391B5-87AC-49D9-A65E-E99C972447C3Q31139428-0F176BE0-F137-4BEF-BEAA-3E50A646E08FQ33255155-75E5A0C8-E3D0-4CDC-88ED-2C54F31A96D8Q33291754-037BC6F5-CBA3-4EF6-986C-229B74BED03CQ33489152-C8B715A2-EA45-4C8A-A848-A8A038A1B438Q33640604-3B0446AE-987C-4B5D-B17A-A0D9C68A440FQ33644718-C24D319D-0DC9-469B-A958-3BA541CECFE7Q33734662-308CCC72-F1CA-44F6-B946-B3C8EE487062Q33790224-5C7C8EA1-C194-413B-AC7C-111E54C86535Q33827954-7B930C90-77AD-400D-AB6C-AB2E1E3539CFQ33831793-959C9CFD-4C00-410E-BAA2-7A828B59041BQ33929560-0A97F153-73B0-4718-8924-373056F9D94CQ34050993-DACB3071-5FBE-425E-A032-70919B380A07Q34053056-D63FCD02-47DA-44B5-8D23-4CCE14313940Q34210139-5AB92AFE-DE81-4DDA-9820-46038EB2D04AQ34299924-8BA003C6-260F-449A-8FA4-740C3620FDFBQ34308962-14791366-0919-4691-9EDC-F179BBE8413AQ34322005-795A8A74-DD90-4FCB-9B26-954C7F99CB84Q34443430-EB0BA331-D7BC-482B-B095-86F0667C54D3Q34449476-8FE3D660-CDA1-4E5A-A917-CF21B01D01FAQ34455567-65635CBC-A391-4229-86DC-649D8607A8CBQ34608717-7EE504C6-5D11-4EE0-8B79-A3E57246585BQ34624765-36E57063-A262-4D93-9B86-A7A63DE449FAQ34689123-6B51C56B-5104-4000-B57B-4212D3F58395Q34861585-AE6605CF-AAA4-4D2B-B4E5-12415A9ED5DFQ35048655-C931C3B2-31A9-43E7-BDF5-D1D0127FE47FQ35088469-F77613AF-3B0B-4855-8619-41233B14EAAD
P2860
Rate of functional decline in Huntington's disease. Huntington Study Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Rate of functional decline in Huntington's disease. Huntington Study Group.
@en
type
label
Rate of functional decline in Huntington's disease. Huntington Study Group.
@en
prefLabel
Rate of functional decline in Huntington's disease. Huntington Study Group.
@en
P2093
P356
P1433
P1476
Rate of functional decline in Huntington's disease. Huntington Study Group.
@en
P2093
I Shoulson
J B Penney
K Kieburtz
M Cudkowicz
P304
P356
10.1212/WNL.54.2.452
P407
P577
2000-01-01T00:00:00Z